Mitsubishi Tanabe Pursues Next Generation Vaccines With Medicago, Tag-teams DPP-4 Market With Daiichi Sankyo
This article was originally published in PharmAsia News
Mitsubishi Tanabe hopes to take on GSK’s Rotarix, the only rotavirus vaccine approved in Japan. And in a crowded DPP-4 field, Mitsubishi looks to double its sales efforts following a deal with Daiichi Sankyo.
You may also be interested in...
Korean Pharmas Rush Into Vaccines: SK Chemicals Breaks Ground For Cell-culture Vaccines With Aid From Xcellerex
SEOUL - South Korea's SK Chemicals joined the race with domestic manufacturers for cell-culture vaccine production, breaking ground June 15 for a cell-culture vaccine plant that will produce vaccines via a biomanufacturing platform from U.S.-based vaccine maker Xcellerex starting in the second half of 2014
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.